Literature DB >> 22116411

Higher executive control and visual memory performance predict treatment completion in borderline personality disorder.

Eric A Fertuck1, John Keilp, Inkyung Song, Melissa C Morris, Scott T Wilson, Beth S Brodsky, Barbara Stanley.   

Abstract

BACKGROUND: Non-completion of a prescribed course of treatment occurs in 20-60% of individuals diagnosed with borderline personality disorder (BPD). While symptom severity, personality traits and environmental factors have been implicated as predictors of treatment non-completion (TNC), there have been no studies of neuropsychological predictors in this population.
METHODS: From a randomized controlled trial, a subsample of 31, unmedicated outpatients diagnosed with BPD with recent self-injurious behavior was assessed on 5 neuropsychological domains. Patients were also assessed for general IQ, demographic and other salient clinical variables. Patients were randomized to one of four treatment conditions, which lasted up to 1 year. Number of weeks in treatment (WIT) up to 1 year was utilized as the index of TNC.
RESULTS: Thirty-three percent of the subsample (n = 12) did not complete 1 year of treatment. However, more WIT were predicted by better baseline executive control (Trails B; p < 0.01) and visual memory performance (Benton visual retention; p < 0.001); other neuropsychological domains did not predict WIT.
CONCLUSION: In the treatment of outpatients with BPD, better executive control and visual memory performance predict more WIT. Assessing and addressing these neurocognitive factors in treatment may reduce TNC in this high-risk population.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116411      PMCID: PMC3242704          DOI: 10.1159/000329700

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  31 in total

1.  Treatment compliance after detoxification among highly disadvantaged alcoholics.

Authors:  R Castaneda; H Lifshutz; M Galanter; A Medalia; H Franco
Journal:  Am J Drug Alcohol Abuse       Date:  1992       Impact factor: 3.829

Review 2.  State of the art in the pharmacologic treatment of borderline personality disorder.

Authors:  Louis Feurino; Kenneth R Silk
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

3.  Neuropsychological dysfunction in depressed suicide attempters.

Authors:  J G Keilp; H A Sackeim; B S Brodsky; M A Oquendo; K M Malone; J J Mann
Journal:  Am J Psychiatry       Date:  2001-05       Impact factor: 18.112

4.  A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem.

Authors:  D A GRANT; E A BERG
Journal:  J Exp Psychol       Date:  1948-08

5.  Is memory impairment a rate limiter in cognitive behavioural therapy for chronic schizophrenia?

Authors:  Rafael Penadés; Rosa Catalán; Núria Pujol; Olga Puig; Joana Guarch; Guillem Masana; Víctor Navarro; Cristóbal Gastó
Journal:  Psychother Psychosom       Date:  2010-01-20       Impact factor: 17.659

6.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

7.  Cognitive deficits predict low treatment retention in cocaine dependent patients.

Authors:  Efrat Aharonovich; Deborah S Hasin; Adam C Brooks; Xinhua Liu; Adam Bisaga; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-09-19       Impact factor: 4.492

8.  The impact of borderline personality disorder and anxiety on neuropsychological performance in major depression.

Authors:  Eric A Fertuck; Sofia Marsano-Jozefowicz; Barbara Stanley; Warren W Tryon; Maria Oquendo; J John Mann; John G Keilp
Journal:  J Pers Disord       Date:  2006-02

9.  Attentional mechanisms of borderline personality disorder.

Authors:  Michael I Posner; Mary K Rothbart; Nathalie Vizueta; Kenneth N Levy; David E Evans; Kathleen M Thomas; John F Clarkin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

10.  Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder.

Authors:  John M Oldham; Donna S Bender; Andrew E Skodol; Ingrid R Dyck; Charles A Sanislow; Shirley Yen; Carlos M Grilo; M Tracie Shea; Mary C Zanarini; Edd John G Gunderson; Thomas H McGlashan
Journal:  J Psychiatr Pract       Date:  2004-05       Impact factor: 1.325

View more
  4 in total

1.  Non-response to psychotherapy for borderline personality disorder: A systematic review.

Authors:  Jane Woodbridge; Michelle Townsend; Samantha Reis; Saniya Singh; Brin Fs Grenyer
Journal:  Aust N Z J Psychiatry       Date:  2021-09-15       Impact factor: 5.598

2.  Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.

Authors:  Haruhiko Banno; Kelly L Andrzejewski; Michael P McDermott; Alyssa Murphy; Madhurima Majumder; Elisabeth A de Blieck; Peggy Auinger; Merit E Cudkowicz; Nazem Atassi
Journal:  J Huntingtons Dis       Date:  2017

3.  Psychological therapies for people with borderline personality disorder.

Authors:  Ole Jakob Storebø; Jutta M Stoffers-Winterling; Birgit A Völlm; Mickey T Kongerslev; Jessica T Mattivi; Mie S Jørgensen; Erlend Faltinsen; Adnan Todorovac; Christian P Sales; Henriette E Callesen; Klaus Lieb; Erik Simonsen
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

4.  Efficacy of cognitive rehabilitation on psychosocial functioning in Borderline Personality Disorder: a randomized controlled trial.

Authors:  Juan C Pascual; Nerea Palomares; Ángela Ibáñez; Maria J Portella; Rocío Arza; Raquel Reyes; Albert Feliu-Soler; Marina Díaz-Marsá; Jerónimo Saiz-Ruiz; Joaquim Soler; Jose L Carrasco
Journal:  BMC Psychiatry       Date:  2015-10-21       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.